Search
Immunocore Holdings PLC
IMCRAdd to Watchlist
32.000USD
-0.300-0.93%
Close 09-18 16:00（ET）
1.65BMarket Cap
LossP/E TTM
Immunocore Holdings PLC (IMCR) Revenue Performance
Updated: Dec 31, 2025Last year, Immunocore Holdings PLC generated 25.95M USD for its biggest-performing segment, Genentech. The United States made the largest contribution, accounting for 257.00M USD last year. For the latest quarter, Immunocore Holdings PLC reported the revenue of 62.91M USD for the period ending 2023-09-30, which came from the top-performing segment, Product revenue. United States contributed the highest revenue, at 45.89M USD.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
Genentech
GlaxoSmithKline
Eli Lilly
MedImmune
FY2020
Genentech
25.95M(67.20%)
GlaxoSmithKline
8.15M(21.11%)
Eli Lilly
4.52M(11.70%)
MedImmune
--(--)
By Region
Revenue
Proportion
Annual
Annual
Quarterly
United States
Europe
International
Collaboration revenue
Europe
United Kingdom
FY2025
FY2024
FY2023
FY2022
FY2020
FY2019
United States
257.00M(64.25%)
226.69M(73.08%)
169.79M(68.07%)
96.89M(55.57%)
30.46M(78.89%)
25.41M(77.59%)
Europe
131.42M(32.85%)
--(--)
--(--)
--(--)
--(--)
--(--)
International
11.60M(2.90%)
10.08M(3.25%)
1.32M(0.53%)
1.05M(0.60%)
--(--)
--(--)
Collaboration revenue
--(--)
213.00K(0.07%)
10.69M(4.29%)
33.67M(19.31%)
--(--)
--(--)
Europe
--(--)
73.22M(23.61%)
67.63M(27.11%)
42.74M(24.52%)
--(--)
--(--)
United Kingdom
--(--)
--(--)
--(--)
--(--)
8.15M(21.11%)
7.34M(22.41%)